Yahoo · Aug 27, 2026
Veeva Systems Inc (VEEV) (Q2 2027) Earnings Call Highlights: Record CRM Quarter and AI Momentum ...
Veeva Systems Inc (VEEV) reports $928 million in revenue and best-ever CRM performance, with Veeva Falcon AI gaining traction.
NASDAQ · BIIB
Biogen Inc.
Healthcare · Drug Manufacturers - General
$218.50
Down-$0.59 (-0.27%)
Updated Aug 31, 2026, 3:00 PM
SID Score
6.7/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 25.33B
- P/E ratio
- 15.74
- Dividend yield
- 0.00%
- 52-week range
- $160.36 – $222.85
- Volume
- 517.48K
- Avg. volume
- 1.8M
Price performance
BIIB price history
1M range · 20 trading sessions · Daily adjusted prices
BIIB closed at $218.50 after 20 trading sessions, up 8.26% for the selected period.
- Last close
- $218.50
- Period change
- +8.26%
- Period low
- $201.82
- Period high
- $221.56
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $221.17 | $222.00 | $216.78 | $218.50 | 517.48K |
| Aug 27, 2026 | $219.39 | $222.11 | $217.53 | $221.50 | 497.52K |
| Aug 26, 2026 | $219.34 | $222.00 | $218.6907 | $221.07 | 647.33K |
| Aug 25, 2026 | $218.93 | $222.85 | $218.00 | $220.77 | 495.44K |
| Aug 24, 2026 | $216.40 | $218.50 | $213.96 | $218.12 | 649.83K |
| Aug 21, 2026 | $217.76 | $219.12 | $215.00 | $216.78 | 722.35K |
| Aug 20, 2026 | $217.98 | $221.29 | $214.16 | $214.35 | 808.63K |
| Aug 19, 2026 | $215.33 | $222.15 | $215.075 | $221.56 | 886.91K |
| Aug 18, 2026 | $211.00 | $214.065 | $210.01 | $212.55 | 694.01K |
| Aug 17, 2026 | $208.36 | $210.49 | $207.62 | $209.15 | 617.24K |
| Aug 14, 2026 | $210.01 | $210.79 | $208.22 | $209.83 | 554.82K |
| Aug 13, 2026 | $212.98 | $215.605 | $208.79 | $210.65 | 860.09K |
| Aug 12, 2026 | $203.52 | $209.22 | $201.00 | $208.87 | 789.44K |
| Aug 11, 2026 | $206.63 | $207.57 | $203.53 | $203.89 | 936.83K |
| Aug 10, 2026 | $206.70 | $210.02 | $206.29 | $207.13 | 706.43K |
| Aug 7, 2026 | $207.38 | $208.31 | $204.16 | $207.94 | 840.57K |
| Aug 6, 2026 | $208.75 | $209.03 | $202.03 | $206.28 | 892.77K |
| Aug 5, 2026 | $210.60 | $212.18 | $205.80 | $206.63 | 873.78K |
| Aug 4, 2026 | $200.96 | $209.74 | $199.9301 | $208.45 | 1.21M |
| Aug 3, 2026 | $203.34 | $203.85 | $199.58 | $201.82 | 940.99K |
Latest BIIB news
The latest Smart Investors Daily articles mentioning BIIB.
Stock researchCompany · Overview
BIIB research
Overview
Company profile and research snapshot.
Company profile
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $177.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 25, 2026 | RBC Capital | Outperform | — |
| Aug 13, 2026 | Wolfe Research | Outperform | — |
| Aug 4, 2026 | Mizuho | Outperform | — |
| Aug 3, 2026 | Citigroup | Neutral | — |
| Jul 30, 2026 | Wedbush | Neutral | — |
News briefing
No generated briefing is available yet.
Yahoo · Aug 26, 2026
Veeva Systems Q2 Earnings Call Highlights
Veeva Systems (NYSE:VEEV) reported fiscal 2027 second-quarter revenue of $928 million and non-GAAP operating income of $416 million, with Chief Executive Officer Peter Gassner saying results exceeded the company’s guidance. Management highlighted record CRM performance, broad commercial-cloud moment
Yahoo · Aug 25, 2026
Veeva's Vault CRM Wins Reinforce Market-Leader Status Ahead of Earnings, Truist Says
Veeva Systems' (VEEV) Vault CRM has cemented its position as the clear market leader in life science
Yahoo · Aug 25, 2026
3 Reasons to Sell BIIB and 1 Stock to Buy Instead
Biogen has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 14.4% to $218.22 per share while the index has gained 10.5%.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
